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Abstract
Background: To assess and compare the prevalence, severity and prognosis of anti-TB drug induced hepatotoxicity (DIH) in
HIV positive and HIV negative tuberculosis (TB) patients in Ethiopia.
Methodology/Principal Findings: In this study, 103 HIV positive and 94 HIV negative TB patients were enrolled. All patients
were evaluated for different risk factors and monitored biochemically and clinically for development of DIH. Sub-clinical
hepatotoxicity was observed in 17.3% of the patients and 8 out of the 197 (4.1%) developed clinical hepatotoxicity. Seven of
the 8 were HIV positive and 2 were positive for HBsAg.
Conclusions/Significance: Sub-clinical hepatotoxicity was significantly associated with HIV co-infection (p=0.002),
concomitant drug intake (p=0.008), and decrease in CD4 count (p=0.001). Stepwise restarting of anti TB treatment was
also successful in almost all the patients who developed clinical DIH. We therefore conclude that anti-TB DIH is a major
problem in HIV-associated TB with a decline in immune status and that there is a need for a regular biochemical and clinical
follow up for those patients who are at risk.
Citation: Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, et al. (2008) Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive
and Negative Patients. PLoS ONE 3(3): e1809. doi:10.1371/journal.pone.0001809
Editor: Landon Myer, University of Cape Town, South Africa
Received May 24, 2007; Accepted February 17, 2008; Published March 19, 2008
Copyright:  2008 Yimer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study done in Ethiopia was fully funded by AHRI, with part of the study done in Sweden funded by Sida/SAREC grant HIV-2006-031.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: getadera@yahoo.com
Introduction
The magnitude of tuberculosis (TB) has increased globally since
1990 due to spread of human immunodeficiency virus (HIV) and
population growth[1]. It is estimated that Mycobacterium tuberculosis
has infected one-third of the world’s population and 8–9 million
new TB cases occur each year. [2–7] In populations with high
HIV prevalence, TB is the leading cause of morbidity and
mortality. [4,6,8]
Hepatotoxicity is one of the most important adverse drug
reactions associated with anti-tuberculosis drugs that may limit
their use.[5] Previous studies showed transient elevations of serum
hepatocellular enzymes (e.g. alanine aminotransferase and aspar-
tate aminotransferase) in approximately 10% of patients who
received a standard combination chemotherapy including isonia-
zid and rifampicin, of these 1–2% patients withdrew from the
treatment because of severe hepatotoxicity that ultimately led to
fulminant hepatitis. [9]
Although the occurrence of drug induced hepatotoxicity (DIH) is
difficult to predict, it has been observed that certain patients are at
higher risk during the course of anti-TB chemotherapy [10–17].
Various studies have suggested that high alcohol intake, older age,
slow acetylation status, pre-existing chronic liver disease, chronic
viral infection due to hepatitis B and hepatitis C, HIV infection,
advanced tuberculosis, Asian ethnicity, female sex, concomitant
administration of enzyme-inducers (e.g. barbiturates and anaesthetic
agents), inappropriate use of drugs and poor nutritional status
increase the risk of anti-tuberculosis drug induced hepatitis. [10–17]
It has been suggested that AIDS is significantly associated with
development of hepatotoxicity.[18] However, the reason for this
association is currently unknown, but may reflect disease-induced
alterations in bioactivation or detoxification of reactive metabo-
lites, as well as immunedysregulation. [19] Besides, there has not
been any study that showed the association between CD4 count
and development of hepatotoxicity among the HIV infected
patients. [9]
In this study, we aimed at determining the possible risk factors
for development of DIH in both HIV-infected (none of which
received ART) and non-infected TB patients from Ethiopia.
Materials and Methods
In this cohort study Ethiopian TB patients were followed and
gave rise to a group of cases of hepatotoxicity and controls (no
hepatotoxicity). The study was conducted from August 2004 to
March 2005, 103 HIV positive and 94 HIV negative consecutive
newly diagnosed male and female adult patients were prospec-
tively evaluated.
Diagnosis of tuberculosis was based on sputum smear, fine
needle aspirate (FNA), and clinical and radiological evidence. The
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guideline for diagnosis of tuberculosis.
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who had smear positive TB were 99, smear negative 39, extra-
pulmonary 32, and disseminated 17. Patients were excluded if they
had a history of prior treatment for tuberculosis, did not consent
for HIV testing, were less than 18 years of age and had clinical
evidence of liver damage prior to starting medication. Patients
were put on DOTS and regimens with rifampicin, isoniazid, and
pyrazinamide (44 patients) or rifampicin, isoniazid, pyrazinamide
and either ethambutol (10 patients) or streptomycin (142 patients)
were given for 2 months of intensive phase (table 1). During the
6 months of continuation phase all patients were put on rifampicin
plus ethambutol.
For all the patients involved in the study a complete history and
physical examination were taken. Laboratory tests done before
initiation of anti-TB drugs included; complete and differential
blood counts, erythrocyte sedimentation rate (ESR), liver function
tests including aspartate aminotransferase (AST), alanine amino-
transferase (ALT), direct and total bilurubin and alkaline
phosphatase, serological tests for hepatitis B surface antigen
(HBsAg) and anti-hepatitis C antibody (anti-HCV). Liver function
tests were performed before initiation of anti-TB drugs and late at
1, 2, 4, 6 and 8 weeks after starting DOTS.
Diagnosis of HIV was made based on the National HIV
diagnosis algorithm using rapid test kits (Determine, Capillus and
Unigold). CD4 count was done for HIV positive patients following
the procedure of Flow cytometer after staining the cells within the
first week of enrolling participants. FACS COUNT, BECTON
DICKINSON, USA is used for counting the CD4 cells.
Sampling
To answer the question that HIV infection is a risk factor for
development of hepatotoxicity in patients taking anti-tuberculosis
therapy we set the level of significance and the power of the study at
5% and 80% respectively. A 2.5% and 25% prevalence of anti-TB
DIH in HIV negative and HIV positive patients respectively was
considered in determining the sample size. The ratio between
patients with TB alone and TB/HIV co-infection was taken as 1:1.
Accordingly the required sample size to detect a minimal difference
in proportion of patients with hepatotoxicity between the HIV
positives and HIV negatives TB patients was 67 per group.
Diagnosis of anti-tuberculosis DIH (Adopted from the
Council for International Organizations of Medical
Sciences (CIOMS) scale)
1. Biochemical DIH (Sub-Clinical hepatotoxicity). Patients
were diagnosed to have biochemical hepatotoxicity if there was no
apparent cause for the raised liver function tests plus if he/she had
one of the following: a rise of five times the upper limit of normal
levels (31 U/L) of serum alanine aminotransferase (ALT) and no
sign and symptom of DIH.
2. Clinical DIH. Clinical hepatotoxicity was diagnosed if a
patient had biochemical hepatotoxicity plus symptoms of DIH
including: nausea, vomiting, weakness and jaundice.
Desensitization protocol for patients who developed
clinical DIH
After discontinuing all the anti-tuberculosis therapy, patients
were followed by both clinically and biochemical parameters for
signs and symptoms of DIH. By the time when all the signs and
symptoms of DIH disappeared and the liver function tests dropped
down to the normal range, patients were reinitiated on their anti-
tuberculosis therapy based on the following protocol. Isoniazid
50 mg per day, followed by isoniazid 100 mg per day, followed by
isoniazid 200 mg and rifampicin 300 mg per day, followed by
RHZ 1tab and RH 2 tabs per day, followed by RHZ 2 tabs and
RH 1 tab per day, followed by RHZE 3 tabs per day, and finally
the normal dose for the patient based on the patients weight.
Desensitization was done every three days and the dosages of
rifampicin and isoniazid in RH were 150 mg and 75 mg,
rifampicin, isoniazid and pyrazinamide in RHZ were 150 mg,
75 mg, and 400 mg and that of rifampicin, isoniazid, pyrazin-
amide and ethambutol in the RHZE were 150 mg, 75 mg,
400 mg, and 275 mg respectively. The intensive phase was also
prolonged by considering as if the patient was not on treatment
during the discontinuation and desensitization period. This
desensitization protocol was adopted from the normal hospital
practice for management of DIH in the study site.
Ethical consideration
The study protocol was approved by two institutional IRBs and
one National Ethical Review Committee which gives the final
decision at the national level. Therefore, ethical approval was
obtained from: IRB of Armauer Hansen research Institute, FRPC
(Faculty research and publication committee) of Faculty Medicine
Addis Ababa University, and the National Health Science and
Technology Council and Ethics Review Committee. Written
informed consent for HIV testing and participation in the study
was obtained from allparticipantsprior tothe commencement ofthe
study. Opportunistic infections were treated free of charge. HIV
positive patients were eventually linked to HIV patients care and
support center. Due to the unavailability of antiretroviral drugs
nationally at the time of the study patients were not provided ART.
Table 1. Risk factors for development of sub-clinical and
clinical hepatotoxicity, Addis Ababa, Ethiopia, August 2004-
March 2005
Variable Status Sub-clinical DIH p-value
Yes No
HIV status Positive 26 (25.2%) 77 (74.8%) 0.002
Negative 8 (8.5%) 86 (91.5%)
Type of TB Pulmonary 25 (17.1%) 121 (82.9%) 0.325
Extra
pulmonary
4 (12.5%) 28 (87.5%)
Disseminated 5 (29.4%) 12 (70.6%)
Anti-TB drugs SRHZ 27 (19.0%) 115 (81.0%) 0.175
ERHZ 3 (30.0%) 7 (70.0%)
RHZ 4 (9.1%) 40 (90.9%)
Concomitant drug
intake
Yes 16 (29.1%) 39 (70.9%) 0.008
No 18 (13.0%) 120 (87.0%)
HbsAg Positive 3 (21.4%) 11 (78.6%) 0.683
Negative 31 (17.1%) 150 (82.9%)
Anti-HCV Antibody Positive 0 (0%) 4 (100%) 1.000
Negative 33 (18.6%) 144 (81.8%)
CD4 count/mm
3 0–50 8 (53.3%) 7 (46.7%) 0.001
51–100 8 (25.0%) 24 (75.0%)
101–200 4 (18.2%) 18 (81.8%)
.200 1 (5.6%) 17 (94.4%)
doi:10.1371/journal.pone.0001809.t001
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Data were double entered and checked. HIV positive and
negative TB patients were compared and SPSS version 11.0 was
used for analysis of the different risk factors for development of
Hepatotoxicity. Chi-square, Fishers exact tests and multivariate
analysis were used to test for the level of significance. Multiple
regression analysis was used to see the effect of different
confounding factors. Clinical and biochemical hepatotoxicity were
the dependant variables whereas age, sex, HBsAg, concomitant
drug intake, HIV status, body mass index, CD4 count and anti-
HCV antibody were the independent variables. OR and P-values
are used to see the significant risk factors. Variables with p,0.05
were considered potential predictors of DIH.
Results
Patients
Out of the 197 study participants 105 (52.8%) were male and 92
(47.2%) were female; the median age of the patients was 26 years
(range, 18 to 67 years). Out of these patients, 103 (52.3%) patients
were HIV positive and 94 (47.7%) patients were negative. CD4
count was done for 87 of the 103 HIV positive patients and the
distribution is shown in Table 1. Eighty percent of the patients had
CD4 count less than 200 cells/mm
3.Fourteen (7.2%) were positive
for HBsAg and only 4 (2.2 %) were positive for anti-HCV.
Among the 195 patients 146 (74.9%) had pulmonary tubercu-
losis of whom 107 (73.3%) had smear positive and 39 (26.7%) had
smear negative TB. Thirty two (16.4%) of the patients had extra
pulmonary TB and 17 (8.7%) had disseminated TB (Table 2).
Only 55 (27.9%) patients from the 197 took other drugs
concomitantly and these drugs were: Vitamin B6 (7 patients), codeine
phosphate (5 patients), promethazine (4 patients) amoxicillin (13
patients), antiacid syrup (13), albendazole (3 patients), tetracycline (2
patients), phenobarbitone (2 patients), ampicillin and gentamincine (2
patients), phenobarbitone plus antiacid syrup (1 patient), ketocona-
zole (1 patient), and trimethoprim/sulfamethoxazole (2 patients).
The Body Mass Index (BMI) of the HIV positive patients was
,18.5 for 61 (59.2%) whereas BMI for the HIV negative patients
was ,18.5 for 47 (50.0%) and the differences were not significant
between the 2 groups of patients (p.0.05)(Table 2). However,
comparison of BMI in patients with and with out DIH was not
done as the number of patients with DIH is very small.
Association of sub-clinical hepatotoxicity with
demographic and clinical variables
Thirty four (17.3%) study participants had sub-clinical hepato-
toxicity of which 8 (4.1%) developed clinical hepatotoxicity with all
of them having jaundice and necessitated discontinuation of their
anti-tuberculosis therapy. Out of the 34 patients 14 (41.2%) were
males and 20 (58.8%) were females. Twenty six (76.5%) were HIV
positive and 8 (23.5%) were negative. Twenty two (66.7%) patients
were ,35 years of age and the mean time for the development of
sub-clinical DIH was 2.8 weeks (Range 1–8 weeks). The mean
duration of stay of the elevated ALT was 2.2 weeks (Range 1–
7 weeks).
Multivariate and bivariate analyses were performed to see the
association between different variables and development of clinical
and biochemical hepatotoxicity. The effect of confounders such as
age, sex, HBsAg, concomitant drug intake, HIV status, body mass
index, CD4 count and anti-HCV antibody was controlled. The
results of the analyses showed that the odds of developing
biochemical hepatotoxicity in patients taking other drugs con-
comitantly was 2.7 with a 95% CI of 1.2–5.8. The odds of
developing biochemical hepatotoxicity in HIV positive patients
was 3.6 with a 95% CI of 1.5–8.5 as compared to that of HIV
negative patients (Table 1, 3 and 4).
Three (21.4%) of the HBsAg positive and 31 (17.1%) of the
HBsAg negative study participants developed sub-clinical hepato-
toxicity whereas none of the 4 anti-HCV positive patients had
hepatotoxicity and no patient was positive for concomitant HBsAg
and anti-HCV Ab.
CD4 count was done for the HIV positive patients and
multivariate analysis to see the association with development of
sub-clinical hepatotoxicity showed that among those patients with
different CD4 count when compared with those with .200/mm
3
the odds ratio is 20.5 with a 95% CI (2.1–195.6) for those with 0–
50/mm
3, 5.9 with a 95% CI (0.6–52.2) for those with 51–100/
mm
3, and 4.2 with a 95% CI (0.4–41.7) for those with 101–200/
mm
3 (Table 1, 3 and 4). This suggests that as the CD4 count
decreases the risk of developing hepatotoxicity also increases.
Table 2. Frequency distribution of demographic and clinical
variables, Addis Ababa, Ethiopia, August 2004-March 2005
Variables Status
Number of
patients (%)
Total number
patients
Age (years) ,35 131 (67.2) 195
$35 64 (32.8)
Sex Male 105 (53.3) 197
Female 92 (46.7)
Body mass index ,18.5 108 (58.7) 184
18.5–24.9 71 (38.6)
25–29.9 5 (2.7)
History of Jaundice Yes 14 (7.2) 194
No 180 (92.8)
History of blood
transfusion
Yes 5 (2.6) 196
No 191 (97.4)
History of chronic illness Yes 5 (2.6) 196
No 191 (97.4)
Traditional medicine
intake
Yes 35 (18.2) 192
No 157 (81.8)
Alcohol intake Yes 74 (38.1) 194
No 120 (61.9)
HIV status Positive 103 (52.3) 197
Negative 94 (47.7)
Type of TB Pulmonary 146 (74.9) 195
Extra pulmonary 32 (16.4)
Disseminated 17 (8.7)
Concomitant drug intake Yes 55 (28.5) 193
No 138 (71.5)
HBsAg Positive 14 (7.2) 195
Negative 181 (92.8)
Anti-HCV Ab Positive 4 (2.2) 181
Negative 177 (97.8)
CD4 count/mm
3 0–50 15 (17.2) 87
51–100 32 (36.8)
101–200 22 (25.3)
.200 18 (20.7)
doi:10.1371/journal.pone.0001809.t002
Tuberculosis, HIV, and DIH
PLoS ONE | www.plosone.org 3 2008 | Volume 3 | Issue 3 | e1809Discussion
The proportion of patients with anti-tuberculosis therapy
induced hepatotoxicity in general has not been studied that often
in African patients. In this study therefore, we studied this
common clinical problem among Ethiopian patients. To effec-
tively study this problem we have excluded patients previously
treated with anti-tuberculosis drugs, critically sick patients as
assessed by level of consciousness and concomitant illnesses, and
patients with baseline liver function test (LFT) values above the
normal range.
The proportion of DIH in HIV positive and HIV negative
patients was statistically significant where HIV positive patients are
at a higher risk than HIV negative ones. Similar findings have
been observed in other studies. [13,20,21] This may be partly
explained by the different drugs used by these patients for the
treatment of AIDS-related opportunistic infections before the
diagnosis of TB was made. Even if the number of patients in the
different groups is small we have also observed that development
of hepatotoxicity had a statistically significant association with
decrement in the immune status of the patients as measured by the
CD4 count. This phenomenon was not shown in previous studies
and may suggest the presence of an immunologic mechanism for
the development of anti-TB DIH although the exact mechanism
has not yet been clearly elucidated. [22] The other possible
explanation for this could be, since patients with low CD4 count
are more prone in acquiring opportunistic infections, this might
necessitate consumption of different drugs leading to sub clinical
liver damage and thereby increase susceptibility for hepatotoxicity
while taking anti TB. [8,23,24]
Unlike previous studies which showed that patients in the older
age group are at increased risk for development of hepatotoxicity,
[13,20,25] in this study, such a finding was not observed and this
could be due to a larger proportion of study participants being in
the age group below 35 years which will make comparison
difficult. However, there are also studies which support that age is
not a risk factor for development of hepatotoxicity in patients
taking anti-tuberculosis therapy. [25–27]
Malnutrition as a risk factor for DIH was suggested by previous
studies. [12,25] However, in this study we did not see any
significant association between malnutrition as measured by BMI
and DIH. Perhaps this may be because of the larger proportion of
study participants having a lower BMI making comparison
difficult. Moreover, similar findings were seen in some other
studies. [22,26]
Being alcoholic is one of the well established risk factors for
DIH. [12,21,22,26] In our study however, we did not see this
association. The reason for this is that even if 74 patients replied
that they have history of alcohol intake it is possible that the levels
of alcohol consumption were not high enough to contribute to
hepatotoxicity.
We have also observed that patients who took drugs
concomitantly with the anti-tuberculosis therapy were at risk for
the development of hepatotoxicity. This could be because of the
synergistic hepatotoxic effect caused by the other drugs. Similar
finding was observed while combining different drugs. [21,28]
Unlike other studies no association between Anti-HCV and
HBsAg positivity and development of hepatotoxicity was observed.
[13,26,29,30] This may be attributed to the small number of
patients who are positive for Anti-HCV antibody and HBsAg in
this study.
This study was conducted at the time were there was no free
antiretroviral drug provision currently however, ART is being
given for free to all those who are in need. The result of this study
might have been affected if there was concurrent treatment with
ART. Findings of this study therefore, would act as a background
for studies that have aimed at identifying risk factors for DIH while
patients take ART and anti-TB drugs concomitantly.
In general we have tried to explore the different risk factors for
the development of anti-tuberculosis DIH in newly diagnosed TB
patients from Ethiopia. We recommend that patients with HIV
infection, low CD4 count and those on other concomitant drugs
Table 3. Unadjusted analyses of the association between
sub-clinical hepatotoxicity with different demographic and
clinical variables, Addis Ababa, August 2004-March 2005
Variable Status OR (95% CI )
HIV status Positive 3.6 (1.5–8.5)
Negative 1.0
Sex Female 1.8 (.8–3.8)
Male 1.0
Age .35 1.1 (.48–2.4)
,35 1.0
BMI $18.5 0.7 (.3–1.5)
,18.5 1.0
Concomitant drug intake No 0.4 (.2–.9)
Yes 1.0
HbsAg Negative 0.7 (.2–2.5)
Positive 1.0
Anti-HCV Ab Negative 1.0 (0.9–1.0)
Positive 1.0
CD4 count/mm3 0–50 21.3 (2.2–204.9)
51–100 5.2 (0.6–46.0)
101–200 4.3 (0.4–42.4)
.200 1.0
doi:10.1371/journal.pone.0001809.t003
Table 4. Multivariate analyses of an association between sub-
clinical hepatotoxicity with different clinical variables, Addis
Ababa, August 2004–March 2005
Variable Status OR (95% CI )
HIV status Positive 3.6 (1.5–8.5)
Negative 1.0
Concomitant drug intake Yes 2.7 (1.2–5.8)
No 1.0
HbsAg Positive 1.3 (.35–5.0)
Negative 1.0
Anti-HCV Antibody Positive 307.5 (0.0–1.2)
Negative 1.0
CD4 count/mm3 0–50 20.5 (2.1–195.6)
51–100 5.9 (0.6–52.2)
101–200 4.2 (0.4–41.7)
.200 1.0
doi:10.1371/journal.pone.0001809.t004
Tuberculosis, HIV, and DIH
PLoS ONE | www.plosone.org 4 2008 | Volume 3 | Issue 3 | e1809have initial screening with liver function test and closely monitored
with subsequent tests during treatment.
We also recommend that further studies should be conducted to
explore the detail mechanism as to why this identified risk factors
contribute for development of hepatotoxicity and also further asses
those risk factors that are not addresses in this study in detailed.
Limitations of the study
Since the main objective of this study was to asses the effect of
HIV infection on development of hepatotoxicity. The sample size
was therefore calculated considering HIV positive and HIV
negative patients. As a result it was difficult to make strong
association on different parameters such as association of
hepatotoxicity with HbsAg, Anti-HCV Antibody and CD4 count.
Moreover, since the majority of our study participants were
underweight it was difficult to see the association between BMI
and hepatotoxicity. The other limitation of the study was
representatives. Since the study was conducted only in one health
institution which was also located in one city there might be a
problem of representing the whole country with regard to
economic status and ethnic group.
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